Risk-adapted treatment selection after nephrectomy
In this studio-based webinar, a multidisciplinary expert panel will address risk-adapted treatment selection after nephrectomy via interactive case discussions on adjuvant therapy in RCC. Expert Panel Philippe Barthélémy, Medical Oncology, Strasbourg Cancer Institute, Strasbourg, France Viktor Grünwald, Medical Oncology, University Hospital Essen, Essen, Germany Sylvie Rottey, Medical Oncology, Ghent University Hospital, Ghent, Belgium Bernadett Szabados, Urology, University College London Hospital & Barts Cancer Institute, London, UK Learning objectives Understand the newest data on adjuvant therapy in RCC Identify which RCC patients are at high risk of recurrence post-nephrectomy and may benefit from adjuvant therapy Choose the most appropriate adjuvant therapy for localised RCC at a patient-specific level EACCME accreditation has been applied for Organised by ISSECAM In collaboration with OncoAlert Supported by an independent educational grant from MSD